In a recent review published in the journal Obesity Pillars , a team of researchers collate and narratively review the literature on the dietary impacts of obesity or type 2 diabetes (T2D) patients undergoing glucagon-like peptide receptor agonists (GLP-1RAs) or glucose-dependent insulinotropic polypeptide/glucagon-like peptide receptor agonists (GIP/GLP-1RAs) clinical interventions
doi: 10.1038/ni1017 70 LinJTLineberryNBKattahMGSuLLUtzPJFathmanCGet al
They warn that loss of coverage could worsen health outcomes and raise future health care costs
While we just launched Somryst commercially, there have been thousands of patients who have used it in research studies, says Yuri Maricich, MD, MBA, chief medical officer and head of development at Pear Therapeutics
Reclaiming your stamina, improving your cognitive function, and promoting overall health are all attainable goals through the proper integration of hormone therapy